The Ontario-based retirement home provider has around 2,000 beds in its health services network, it said.
"As an industry leader with over 40 years of experience providing quality health care to its residents, Jarlette Health Services is a welcome addition to our growing network of LTC, assisted living and retirement homes looking to enhance the quality of life of their residents," said Bruce Dawson-Scully, chief executive of WeedMD.
"This partnership exemplifies Jarlette's forward-looking approach to the use of medical cannabis as an alternative medicine."
In September this year, the company reported a supply deal with three providers - peopleCare Communities, Arbour Heights and the Belmont Long Term Care Facility, totalling over 1,000 beds across the state.
WeedMD will now be the preferred supplier of medical cannabis to Jarlette's 14 LTC (long term care) homes and six retirement lodges across the province.
With the addition of Jarlette, WeedMD is now the preferred supplier for 29 LTC homes and lodges, representing more than 3,000 beds, the group said in a statement today.
Judy Maltais, director of long term care operations at Jarlette Health Services, added: "We've been researching the use of medical cannabis for some time and are pleased to add education and collaboration in resident care to improve and optimize medication therapy for our residents.
"Through education and training, we are working with WeedMD to provide support to our residents and their families. Making investments in education will ensure that our residents and Jarlette's network of health care providers are equipped with the tools to make informed decisions about medical cannabis," said Edwin Brunink, Director of Retirement Lodge Operations, Jarlette Health Services.
Having secured a license from Health Canada on December 1, 2017 to sell cannabis oils, WeedMD's product offerings include two cannabis oil platforms called Axis (for the LTC market) and Entourage (for patients registered under the ACMPR program).
All three products will be available for purchase by current medical partners and patients via WeedMD's website as of early 2018, it said.
Shares added 2.97% in Toronto to C$2.43..